Premium
Remdesivir: an antiviral for the treatment of COVID ‐19
Author(s) -
Chaplin Steve
Publication year - 2020
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1859
Subject(s) - medicine , covid-19 , antiviral treatment , antiviral drug , antiviral therapy , virology , drug , mode of action , pharmacology , virus , toxicology , infectious disease (medical specialty) , outbreak , disease , chronic hepatitis , biology
The antiviral remdesivir (Veklury) is the first drug to be licensed for the treatment of COVID‐19. This article discusses its mode of action, indications, clinical trial efficacy and side‐effects.